ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för lestaurtinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

20 träffar

Bibliografisk träff 2024-06-06

Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity.

Miao Y, Virtanen A, Zmajkovic J, Hilpert M, Skoda RC, Silvennoinen O, Haikarainen T.

J Med Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1021/acs.jmedchem.4c00197

Bibliografisk träff 2023-05-30

Design and Synthesis of Pyrazole-Based Macrocyclic Kinase Inhibitors Targeting BMPR2.

Amrhein JA, Wang G, Berger BT, Berger LM, Kalampaliki AD, Krämer A, Knapp S, Hanke T.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.3c00127

Bibliografisk träff 2023-04-20

Deciphering the multifunctional role of dual leucine zipper kinase (DLK) and its therapeutic potential in disease.

Bu H, Li Z, Lu Y, Zhuang Z, Zhen Y, Zhang L.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2023.115404

Bibliografisk träff 2022-06-18

Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.

Shen P, Wang Y, Jia X, Xu P, Qin L, Feng X, Li Z, Qiu Z.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2022.114551

Bibliografisk träff 2022-05-23

FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms.

Acharya B, Saha D, Armstrong D, Lakkaniga NR, Frett B.

RSC Med Chem · review-article; review; journal article · DOI 10.1039/d2md00067a

Bibliografisk träff 2021-12-30

Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.

Dokla EME, Abdel-Aziz AK, Milik SN, McPhillie MJ, Minucci S, Abouzid KAM.

Bioorg Med Chem · journal article · DOI 10.1016/j.bmc.2021.116596

Bibliografisk träff 2021-12-16

ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders.

Demuro S, Sauvey C, Tripathi SK, Di Martino RMC, Shi D, Ortega JA, Russo D, Balboni B, Giabbai B, Storici P, Girotto S, Abagyan R, Cavalli A.

Eur J Med Chem · research-article; journal article · DOI 10.1016/j.ejmech.2021.114054

Bibliografisk träff 2021-02-04

Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.

Raghuvanshi R, Bharate SB.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.0c01467

Bibliografisk träff 2020-07-21

Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia.

Zhong Y, Qiu RZ, Sun SL, Zhao C, Fan TY, Chen M, Li NG, Shi ZH.

J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.0c00696

Bibliografisk träff 2020-03-06

Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia.

Jeong P, Moon Y, Lee JH, Lee SD, Park J, Lee J, Kim J, Lee HJ, Kim NY, Choi J, Heo JD, Shin JE, Park HW, Kim YG, Han SY, Kim YC.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2020.112205

Bibliografisk träff 2017-12-01

The target landscape of clinical kinase drugs.

Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C, Zecha J, Reiter K, Qiao H, Helm D, Koch H, Schoof M, Canevari G, Casale E, Depaolini SR, Feuchtinger A, Wu Z, Schmidt T, Rueckert L, Becker W, Huenges J, Garz AK, Gohlke BO, Zolg DP, Kayser G, Vooder T, Preissner R, Hahne H, Tõnisson N, Kramer K, Götze K, Bassermann F, Schlegl J, Ehrlich HC, Aiche S, Walch A, Greif PA, Schneider S, Felder ER, Ruland J, Médard G, Jeremias I, Spiekermann K, Kuster B.

Science · research support, non-u.s. gov't; research-article; journal article · DOI 10.1126/science.aan4368

Bibliografisk träff 2015-08-01

Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.

Siegel MB, Liu SQ, Davare MA, Spurgeon SE, Loriaux MM, Druker BJ, Scott EC, Tyner JW.

Oncotarget · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.18632/oncotarget.4214

Bibliografisk träff 2013-10-03

Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.

Goodfellow VS, Loweth CJ, Ravula SB, Wiemann T, Nguyen T, Xu Y, Todd DE, Sheppard D, Pollack S, Polesskaya O, Marker DF, Dewhurst S, Gelbard HA.

J Med Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/jm401094t

Bibliografisk träff 2013-01-26

Flavonoids as receptor tyrosine kinase FLT3 inhibitors.

Chin YW, Kong JY, Han SY.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2013.01.049

Bibliografisk träff 2011-10-30

Comprehensive analysis of kinase inhibitor selectivity.

Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP.

Nat Biotechnol · journal article · DOI 10.1038/nbt.1990

Bibliografisk träff 2010-01-28

Colony stimulating factor-1 receptor as a target for small molecule inhibitors.

Mashkani B, Griffith R, Ashman LK.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2010.01.056

Bibliografisk träff 2010-01-20

Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells.

Choi SJ, Moon MJ, Lee SD, Choi SU, Han SY, Kim YC.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2010.01.039

Bibliografisk träff 2009-08-04

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q, Sprankle KG, Patel HK, Levis M, Armstrong RC, James J, Bhagwat SS.

Blood · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1182/blood-2009-05-222034

Bibliografisk träff 2009-03-19

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.

Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A.

Leukemia · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1038/leu.2009.50

Bibliografisk träff 2004-02-01

Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles.

Wood ER, Kuyper L, Petrov KG, Hunter RN, Harris PA, Lackey K.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2003.12.002